Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
159.34M | 120.51M | 91.64M | 82.40M | 75.22M | Gross Profit |
53.65M | 40.79M | 29.25M | 20.89M | 21.39M | EBIT |
5.43M | -2.38M | -4.35M | -17.05M | 122.00K | EBITDA |
8.31M | 1.86M | -721.00K | -14.68M | -1.80M | Net Income Common Stockholders |
3.12M | -2.21M | -4.55M | -14.62M | -6.58M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
19.27M | 16.04M | 18.79M | 20.50M | 2.31M | Total Assets |
103.02M | 87.64M | 93.86M | 90.94M | 54.66M | Total Debt |
12.60M | 15.39M | 19.44M | 22.94M | 22.33M | Net Debt |
-6.67M | -646.00K | 648.00K | 2.44M | 20.02M | Total Liabilities |
45.13M | 36.20M | 40.16M | 36.16M | 55.23M | Stockholders Equity |
57.89M | 51.45M | 53.71M | 54.78M | -573.00K |
Cash Flow | Free Cash Flow | |||
9.88M | 1.84M | 4.42M | -23.09M | 3.96M | Operating Cash Flow |
13.04M | 2.40M | 4.68M | -19.46M | 4.18M | Investing Cash Flow |
-3.15M | -563.00K | -258.00K | -3.63M | -225.00K | Financing Cash Flow |
-5.02M | -5.07M | -5.13M | 41.48M | -4.84M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | C$454.82M | 97.62 | 8.21% | ― | 34.10% | ― | |
73 Outperform | C$1.92B | 12.06 | 14.49% | 2.78% | 0.47% | 9.41% | |
65 Neutral | C$416.94M | 14.16 | 5.95% | 2.79% | 5.97% | 174.18% | |
62 Neutral | $6.84B | 11.41 | 2.80% | 3.87% | 2.70% | -24.58% | |
51 Neutral | C$7.11M | ― | 204.61% | ― | -10.48% | 94.56% | |
48 Neutral | $6.46M | ― | ― | -36.77% | 83.80% |
Kits Eyecare Ltd. announced the results of its 2025 Annual General Meeting, where all proposed resolutions were passed, including the election of six directors and the re-appointment of MNP LLP as auditors. The voting results reflect strong shareholder support, positioning the company to continue its focus on innovation and customer satisfaction in the digital eyecare industry.
The most recent analyst rating on (TSE:KITS) stock is a Buy with a C$11.25 price target. To see the full list of analyst forecasts on Kits Eyecare stock, see the TSE:KITS Stock Forecast page.
Kits Eyecare Ltd. reported a record-breaking first quarter in 2025, with a 34% increase in revenue year-over-year, reaching $46.6 million. The company’s adjusted EBITDA also improved significantly to $3.5 million, marking its tenth consecutive quarter of positive adjusted EBITDA. The growth was driven by increased sales of glasses, with 104,000 pairs delivered, and a focus on acquiring high-value customers. This financial performance underscores the strength of Kits’ vertically integrated model and its strategic focus on operational efficiency, positioning the company for sustained profitable growth.